GENE Genetic Technologies Ltd

Date: December 19, 2014

GENETIC TECHNOLOGIES LIMITED

By:

/s/ Bronwyn Christie

Name: Bronwyn Christie

Title: Company Secretary

Exhibit

Description of Exhibit

99.1

ASX Announcement, December 19, 2014

99.2

Appendix 3B, December 19, 2014

Ms. Alison Mew

Mr. Eutillio Buccilli

Candice Knoll (USA)

Chief Executive Officer

Chief Operating Officer &

Blueprint Life Science Group

Chief Financial Officer

+1 (415) 375 3340, Ext. 105

Genetic Technologies Limited

Genetic Technologies Limited

+61 3 8412 7009

+ 61 3 8412 7050

1

+Class of +securities issued or to be issued

Ordinary shares

2

Number of +securities issued or to be issued (if known) or maximum number which may be issued

7,848,862 in respect of conversion of 100,000 convertible notes

210,737 in respect of interest accrued under the convertible note

3

Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares

4

Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

·                  the date from which they do

·                  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

·                  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Yes

5

Issue price or consideration

The face value of Convertible Notes converted at $1.00 per note ($100,000), plus interest accrued ($2,685).There will be no additional funds received by the Company for the Notes becoming Convertible Notes.

6

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

To provide the Company with general working capital and to fund the continuing commercialisation and to facilitate the acceptance and growth of the Company’s flagship lead breast cancer risk test BREVAGenplusTM.

6a

Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b — 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

No

6b

The date the security holder resolution under rule 7.1A was passed

Not applicable

6c

Number of +securities issued without security holder approval under rule 7.1

Not applicable

6d

Number of +securities issued with security holder approval under rule 7.1A

Not applicable

6e

Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

Not applicable

6f

Number of securities issued under an exception in rule 7.2

Not applicable

6g

If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3?  Include the issue date and both values.  Include the source of the VWAP calculation.

Not applicable

6h

If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

Not applicable

6i

Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A — complete Annexure 1 and release to ASX Market Announcements

110,956,555

7

Dates of entering +securities into uncertificated holdings or despatch of certificates

19 December 2014

Number

+Class

8

Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)

820,849,917

Ordinary shares

Number

+Class

9

Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)

1,875,000

Options at $0.19, exp. 31/3/2016 (GTGAW)

1,000,000

Options at $0.20, exp. 31/7/2016 (GTGAM)

750,000

Options at $0.12, exp. 20/2/2017 (GTGAK)

2,650,000

Options at $0.14, exp. 29/8/2017 (GTGAO)

250,000

Options at $0.10, exp. 1/12/17 (GTGAQ)

500,000

Options at $0.10, exp. 25/1/18 (GTGAS)

750,000

Options at $0.105, exp. 11/7/18 (GTGAY)

6,875,000

Options at $0.04, exp. 31/5/19 (GTGAA)

1,600,000

Convertible Notes issued on 3 December 2014 (GTGAB)

143,333,333

Options at $0.015, exp. 2/12/2018 (GTGAC)

10

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

11

Is security holder approval required?

12

Is the issue renounceable or non-renounceable?

13

Ratio in which the +securities will be offered

14

+Class of +securities to which the offer relates

15

+Record date to determine entitlements

16

Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

17

Policy for deciding entitlements in relation to fractions

18

Names of countries in which the entity has +security holders who will not be sent new issue documents

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

19

Closing date for receipt of acceptances or renunciations

20

Names of any underwriters

21

Amount of any underwriting fee or commission

22

Names of any brokers to the issue

23

Fee or commission payable to the broker to the issue

24

Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders

25

If the issue is contingent on +security holders’ approval, the date of the meeting

26

Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled

27

If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders

28

Date rights trading will begin (if applicable)

29

Date rights trading will end (if applicable)

30

How do +security holders sell their entitlements in full through a broker?

31

How do +security holders sell part of their entitlements through a broker and accept for the balance?

32

How do +security holders dispose of their entitlements (except by sale through a broker)?

33

+Despatch date

34

Type of securities

(tick one)

(a)

x

Securities described in Part 1

(b)

o

All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Tick to indicate you are providing the information or documents

35

o

If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36

o

If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

37

o

A copy of any trust deed for the additional +securities

38

Number of securities for which +quotation is sought

39

Class of +securities for which quotation is sought

40

Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

·             the date from which they do

·             the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

·             the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41

Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

Number

+Class

42

Number and +class of all +securities quoted on ASX

(including the securities in clause 38)

Sign here:

Date: 19 December 2014

Chief Executive Officer

Print name:

Alison Mew

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue

572,694,101

Add the following:

·             Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2

·             Number of fully paid ordinary securities issued in that 12 month period with shareholder approval

·             Number of partly paid ordinary securities that became fully paid in that 12 month period

Note:

·             Include only ordinary securities here — other classes of equity securities cannot be added

·             Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

·             It may be useful to set out issues of securities on different dates as separate line items

313,509,896

Subtract the number of fully paid ordinary securities cancelled during that 12 month period

75,937,500

“A”

810,266,497

Step 2: Calculate 15% of “A”

“B”

0.15

[Note: this value cannot be changed]

Multiply “A” by 0.15

121,539,975

Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used

Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:

·                  Under an exception in rule 7.2

·                  Under rule 7.1A

·                  With security holder approval under rule 7.1 or rule 7.4

Note:

·                  This applies to equity securities, unless specifically excluded — not just ordinary securities

·                  Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

·                  It may be useful to set out issues of securities on different dates as separate line items

“C”

10,583,420

Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1

“A” x 0.15

121,539,975

Note: number must be same as shown in Step 2

Subtract “C”

10,583,420

Note: number must be same as shown in Step 3

Total [“A” x 0.15] – “C”

110,956,555

[Note: this is the remaining placement capacity under rule 7.1]

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

“A”

Note: number must be same as shown in Step 1 of Part 1

Step 2: Calculate 10% of “A”

“D”

0.10

Note: this value cannot be changed

Multiply “A” by 0.10

Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used

Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A

Notes:

·             This applies to equity securities — not just ordinary securities

·             Include here — if applicable — the securities the subject of the Appendix 3B to which this form is annexed

·             Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained

·             It may be useful to set out issues of securities on different dates as separate line items

“E”

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A

“A” x 0.10

Note: number must be same as shown in Step 2

Subtract “E”

Note: number must be same as shown in Step 3

Total [“A” x 0.10] – “E”

Note: this is the remaining placement capacity under rule 7.1A